

Priestley Katherine
 Form 3
 May 03, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â F2 Bioscience III, L.P.
 (Last) (First) (Middle)

UGLAND HOUSE, SOUTH CHURCH STREET,Â PO BOX 309
 (Street)

GEORGE TOWN,Â E9Â KY1-1104
 (City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
 04/23/2013

3. Issuer Name and Ticker or Trading Symbol
 Radius Health, Inc. [NONE]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
 ___ Officer ___ Other
 (give title below) (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___ Form filed by One Reporting Person
 ___X___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

Date Exercisable Expiration Date

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

Title Amount or Number of

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Edgar Filing: Priestley Katherine - Form 3

| | | | | Shares | | or Indirect (1) (Instr. 5) | |
|--------------------------------------|------------|------------|--------------|-----------|----------|----------------------------------|---|
| Series B Convertible Preferred Stock | 04/23/2013 | Â (1) | Common Stock | 3,256,270 | \$ (1) | D (2) | Â |
| Common Stock Warrant | 04/23/2013 | 04/23/2018 | Common Stock | 814,068 | \$ 6.142 | D (2) | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| F2 Bioscience III, L.P. UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 GEORGE TOWN,Â E9Â KY1-1104 | Â | Â X | Â | Â |
| F2 Bioscience GP Ltd. UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 GEORGE TOWN,Â E9Â KY1-1104 | Â | Â X | Â | Â |
| F2 Capital Ltd UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 GEORGE TOWN,Â E9Â KY1-1104 | Â | Â X | Â | Â |
| Priestley Katherine UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 GEORGE TOWN,Â E9Â KY1-1104 | Â | Â X | Â | Â |

Signatures

| | |
|---|------------|
| /s/ Morag Law, attorney-in-fact for F2 Bioscience III, L.P. | 05/03/2013 |
| __Signature of Reporting Person | Date |
| /s/ Morag Law, attorney-in-fact for F2 Bioscience GP Ltd. | 05/03/2013 |
| __Signature of Reporting Person | Date |
| /s/ Morag Law, attorney-in-fact for F2 Capital Limited | 05/03/2013 |
| __Signature of Reporting Person | Date |
| /s/ Morag Law, attorney-in-fact for Kathrine Priestley | 05/03/2013 |
| __Signature of Reporting Person | Date |

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each share of the Series B Convertible Preferred Stock has no expiration date and is convertible at any time, in whole or in part, at the election of the holder at a conversion rate of 10 shares of Common Stock for every 1 share of Series B Convertible Preferred Stock.

The reported securities are owned directly by F2 Bioscience III, L.P. ("F2"). Each of F2 Biosciences GP Ltd. ("F2 GP"), Katherine Priestley and F2 Capital Limited ("F2 Capital") are indirect beneficial owners of the reported securities. F2 GP is the General Partner of

(2) F2 and Katherine Priestley is a member of F2 GP. F2 Capital is an investment adviser to F2. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.